| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US4959366 | PFIZER | Anti-arrhythmic agents |
Sep, 2012
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6124363 | PFIZER | Dofetilide polymorphs |
Oct, 2018
(5 years ago) | |
Tikosyn is owned by Pfizer.
Tikosyn contains Dofetilide.
Tikosyn has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Tikosyn are:
- US6124363
- US4959366
Tikosyn was authorised for market use on 01 October, 1999.
Tikosyn is available in capsule;oral dosage forms.
Tikosyn can be used as treatment of cardiac arrhythmia.
The generics of Tikosyn are possible to be released after 09 October, 2018.
Drugs and Companies using DOFETILIDE ingredient
Market Authorisation Date: 01 October, 1999
Treatment: Treatment of cardiac arrhythmia
Dosage: CAPSULE;ORAL
How can I launch a generic of TIKOSYN before it's drug patent expiration?
More Information on Dosage
TIKOSYN family patents
